Citations

Clear

1792 citation(s) found for "Stephanie".

When Should Asymptomatic Persons Be Tested for COVID-19?
Schuetz, Audrey N. , Mehta, Ninad , Campbell, Sheldon , Mitchell, Stephanie L. , Palavecino, Elizabeth , Butler‐Wu, Susan M. , Mehta, Ninad , Mitchell, Stephanie , Butler-Wu, Susan , Schuetz, Audrey N , Hemarajata, Peera , Miller, Melissa B.

Mayo Clinic

Journal of Clinical Microbiology | October 7, 2020 | Volume: 59 | Issue: 1 | Pages: No page available

10.1128/jcm.02563-20 | PMID 33023910 Get It

On 24 August 2020, the Centers for Disease Control and Prevention (CDC) updated its website to highlight that asymptomatic individuals, even those with exposure to a COVID-19-positive contact, do not necessarily need to be tested unless they have medical conditions associated with increased risk of severe illness from COVID-19. The CDC subsequently updated its guidance on 19 September 2020 to support testing of asymptomatic persons, including close contacts of persons with documented SARS-CoV-2 infection.
Application, Verification, and Implementation of SARS-CoV-2 Serologic Assays with Emergency Use Authorization
Theel, Elitza S. , Couturier, Marc Roger , Filkins, Laura , Palavecino, Elizabeth , Mitchell, Stephanie L. , Campbell, Sheldon , Pentella, Michael , Butler‐Wu, Susan M. , Jerke, Kurt, Dharmarha, Vaishali, McNult, Peggy, Mitchell, Stephanie , Butler-Wu, Susan , Schuetz, Audrey N , Schuetz, Audrey N.

Mayo Clinic

Journal of Clinical Microbiology | October 6, 2020 | Volume: 59 | Issue: 1 | Pages: No page available

10.1128/jcm.02148-20 | PMID 33020185 Get It

Interest continues to grow regarding the role of serologic assays for the detection of prior infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The U.S. Food and Drug Administration (FDA) has granted emergency use authorization (EUA) status to many SARS-CoV-2 serologic assays. In this document, expert recommendations from clinical microbiologist members of the American Society for Microbiology (ASM) concerning detailed verification strategies for SARS-CoV-2 serologic assays with FDA EUA are provided, as are insights into assay limitations and reporting considerations for laboratories.
Prenatal characterization of a novel inverted SMAD2 duplication by mate-pair sequencing in a fetus with dextrocardia
Mendoza, Cinthya Zepeda, Essendrup, Anna, Smoley, Stephanie A., Johnson, Sarah H. , Hoppman, Nicole L., Vasmatzis, George , Jackson, Daniel L. , Kearney, Hutton M. , Zepeda‐Mendoza, Cinthya , Baughn, Linda B.

Mayo Clinic

No container title available | October 1, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.160157600.00947118 Get It

A fetus harboring a duplication of SMAD2 exons 1-6 presented with dextrocardia and pulmonary hypoplasia. Mate-pair sequencing revealed the duplication to be in inverted tandem orientation to the wild-type SMAD2 allele, disrupting its sequence and decreasing expression. These observations suggest SMAD2 to be responsible for the fetal dextrocardia.
Occipital-Cervical Fusion and Ventral Decompression in the Surgical Management of Chiari-1 Malformation and Syringomyelia: Analysis of Data From the Park-Reeves Syringomyelia Research Consortium
CreveCoeur, Travis S. , Yahanda, Alexander T. , Maher, Cormac O. , Johnson, Gabrielle W. , Ackerman, Laurie L. , Adelson, P. David , Albert, Gregory W. , Aldana, Phillipp R, Alden, Tord D. , Anderson, Richard C. E. , Baird, Lissa , Bauer, David F. , Bierbrauer, Karin S. , Brockmeyer, Douglas L. , Chern, Joshua J. , Couture, Daniel E., Daniels, David, Dauser, Robert C., Durham, Susan, Ellenbogen, Richard G. , Eskandari, Ramin , Fuchs, Herbert E., George, Timothy M., Greene, Stephanie , Gross, Naina L. , Guillaume, Daniel, Hankinson, Todd C. , Heuer, Gregory G. , Iantosca, Mark, Iskandar, Bermans J. , Jackson, Eric M. , Jea, Andrew, Johnston, James M. , Keating, Robert F., Kelly, Michael P. , Khan, Nickalus R. , Krieger, Mark D., Leonard, Jeffrey R. , Mangano, Francesco T. , Mapstone, Timothy B., McComb, J. Gordon , Muhlbauer, Michael S., Oakes, W. Jerry, Olavarria, Greg, O’Neill, Brent R., Park, Tae Sung, Ragheb, John , Shannon, Chevis N. , Smith, Jodi L. , Stone, Scellig , Strahle, Jennifer M. , Tamber, Mandeep S. , Torner, James C., Tuite, Gerald F. , Wait, Scott D. , Wellons, John C. , Whitehead, William E. , Limbrick, David D. , Torner, James C. , Kelly, Michael P , Yahanda, Alexander T , Ahmed, Raheel , Aldana, Phillip R., Grant, Gerald A. , Graupman, Patrick C. , Greenfield, Jeffrey P. , Guillaume, Daniel J, Haller, Gabe , Menezes, Arnold H. , Selden, Nathan R. W. , Shah, Manish N. , Shimony, Joshua S. , Limbrick, David D.

Mayo Clinic

Neurosurgery | September 22, 2020 | Volume: 88 | Issue: 2 | Pages: 332-341

10.1093/neuros/nyaa460 | PMID 33313928 Get It

Abstract BACKGROUND Occipital-cervical fusion (OCF) and ventral decompression (VD) may be used in the treatment of pediatric Chiari-1 malformation (CM-1) with syringomyelia (SM) as adjuncts to posterior fossa decompression (PFD) for complex craniovertebral junction pathology. OBJECTIVE To examine factors influencing the use of OCF and OCF/VD in a multicenter cohort of pediatric CM-1 and SM subjects treated with PFD. METHODS The Park-Reeves Syringomyelia Research Consortium registry was used to examine 637 subjects with cerebellar tonsillar ectopia ≥ 5 mm, syrinx diameter ≥ 3 mm, and at least 1 yr of follow-up after their index PFD. Comparisons were made between subjects who received PFD alone and those with PFD + OCF or PFD + OCF/VD. RESULTS All 637 patients underwent PFD, 505 (79.2%) with and 132 (20.8%) without duraplasty. A total of 12 subjects went on to have OCF at some point in their management (PFD + OCF), whereas 4 had OCF and VD (PFD + OCF/VD). Of those with complete data, a history of platybasia (3/10, P = .011), Klippel-Feil (2/10, P = .015), and basilar invagination (3/12, P < .001) were increased within the OCF group, whereas only basilar invagination (1/4, P < .001) was increased in the OCF/VD group. Clivo-axial angle (CXA) was significantly lower for both OCF (128.8 ± 15.3°, P = .008) and OCF/VD (115.0 ± 11.6°, P = .025) groups when compared to PFD-only group (145.3 ± 12.7°). pB-C2 did not differ among groups. CONCLUSION Although PFD alone is adequate for treating the vast majority of CM-1/SM patients, OCF or OCF/VD may be occasionally utilized. Cranial base and spine pathologies and CXA may provide insight into the need for OCF and/or OCF/VD.
Genomics combined with a protein informatics platform to assess a novel pathogenic variant c.1024 A>G (p.K342E) in OPA1 in a patient with autosomal dominant optic atrophy
Ahuja, Abhimanyu S. , Selvam, Pavalan , Vadlamudi, Charitha , Chopra, Hayley, Richter, John E. , Macklin, Sarah , Samreen, Ayesha , Helmi, Haytham , Mohammaad, Ahmed N., Hines, Stephanie L., Davila, Maria C., Caulfield, Thomas R. , Hines, Stephanie, Caulfield, Thomas R , Samreen, Ayesha , Ahuja, Abhimanyu , Atwal, Paldeep S

Mayo Clinic

Ophthalmic Genetics | September 17, 2020 | Volume: 41 | Issue: 6 | Pages: 563-569

10.1080/13816810.2020.1814344 | PMID 32940104 Get It

The NEALS primary lateral sclerosis registry
Chan, James , Thrower, Sara, Staff, Nathan P. , Datta, Neil, Kisanuki, Yaz Y. , Drory, Vivian E., Fournier, Christina , Goutman, Stephen A. , Atassi, Nazem , Group, On behalf of the NEALS PLS Registry Study, Jeon, Maryangel, Caldwell, Sarah, McDonough, Timothy, Gentile, Caroline, Liu, Jianing , Turner, M.F., Denny, Carol, Felice, Kevin J. , Green, Misty, Scarberry, Stephanie, Abu-Saleh, Saad, Nefussy, Beatrice, Hastings, Debbie, Kim, S. K., Swihart, Blake, Arcila-Londono, Ximena , Newman, Daniel S. , Silverman, Michael G. , Genge, Angela , Salmon, Kristiana , Elman, Lauren , McCluskey, Leo, Almasy, Kelly, Goslin, Kimberly, CUMMINGS, A. J., Edwards, Eli K., Rivner, Michael H. , Bouchard, Kristy, Quarles, Brandy, Kwan, Justin , Jaffa, Matthew , Baloh, Robert H. , Allred, Peggy, Walk, David , Maiser, Samuel, Manousakis, Georgios , Ferment, Valerie, Fernandes, J. Americo, Thaisetthawatkul, Pariwat , Heimes, Deborah, Sams, Laura, Kahler, Melissa, Corcoran, Alecia, Larriviere, Daniel G., Chotto, Sadie, Juba, Gracy, Staff, Nathan P , Turner, Michelle, Goutman, Stephen A , Walk, David , Paganoni, Sabrina , Marchi, Fabiola De , Pioro, Erik P. , Group, On behalf of the NEALS PLS Registry Study, Caldwell, Sarah, Mcdonough, Timothy, Turner, Michelle, Denny, C. Dimla, Newman, Daniel S., Silverman, Michael, Gotkine, Marc , Cummings, Arlena, Phillips, Melissa

Mayo Clinic

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration | September 11, 2020 | Volume: 21 | Issue: sup1 | Pages: 74-81

10.1080/21678421.2020.1804591 | PMID 32915077 Get It

Sexual Health in Women
Kling, Juliana M. , Kapoor, Ekta , Kling, Juliana M , Faubion, Stephanie S. , Kapoor, Ekta

Mayo Clinic

Journal of Women's Health | September 8, 2020 | Volume: 30 | Issue: 3 | Pages: 301-304

10.1089/jwh.2020.8730 | PMID 32898453 Get It

Intensive Multicomponent Fibromyalgia Treatment
Bruce, Barbara K. , Allman, Madeleine E, Rivera, Fernando A, Berianu, Florentina , Butendieck, Ronald R., Calamia, Kenneth , Hines, Stephanie L., Rummans, Teresa A. , Niazi, Shehzad K. , Abril, Andy , Allman, Madeleine E, Rivera, Fernando A, Wang, Benjamin X.

Mayo Clinic

JCR: Journal of Clinical Rheumatology | September 6, 2020 | Volume: 27 | Issue: 8 | Pages: e496-e500

10.1097/rhu.0000000000001555 | PMID 32897994 Get It

Objective The current study was designed to evaluate the translation of clinical trial outcomes and clinical guidelines for the treatment of fibromyalgia (FM) into an intensive multicomponent clinical program embedded in routine care delivery. The study aimed to assess the adaptation of these recommended strategies into routine clinical care while evaluating their effectiveness and durability in improving functional status and level of distress in a large clinical sample of FM patients. Methods Four hundred eighty-nine patients with FM completed a 2-day program that incorporated best practice recommendations for the treatment of FM. Patients completed the Fibromyalgia Impact Questionnaire–Revised, the Center for Epidemiologic Studies Depression Scale, and the Pain Catastrophizing Scale at admission to the program and at follow-up on average 5 months posttreatment. Results Significant improvements were seen in functional status (p < 0.0001), depressive symptoms (p < 0.0001), and pain catastrophizing (p < 0.0001) after participation in the intensive multicomponent treatment program. Conclusions The present study shows that an intensive multicomponent treatment program embedded in routine care delivery is effective in significantly improving functional status and psychological distress in a large sample of FM patients. The significant improvements were durable and maintained at follow-up.
Percutaneous Axillary Intra-aortic Balloon Pump Insertion Technique as Bridge to Advanced Heart Failure Therapy
Rosenbaum, Andrew , Jain, C. Charles , Shadrin, Ilya Y. , Hajj, Stephanie C. El , Sabbagh, Abdallah El , Behfar, Atta , Rosenbaum, Andrew N , Behfar, Atta , Hajj, Stephanie C. El

Mayo Clinic

ASAIO Journal | September 6, 2020 | Volume: 67 | Issue: 4 | Pages: e81-e85

10.1097/mat.0000000000001259 | PMID 33770002 Get It

In patients with advanced heart failure (HF), temporary mechanical circulator support (TMCS) is used to improve hemodynamics, via left ventricular unloading, and end-organ function as a bridge to definitive therapy. While listed for cardiac transplantation, use of TMCS may be prolonged, preventing adequate mobility. Here, we describe the technique for placement of a percutaneous axillary intra-aortic balloon pump (IABP) using single-site arterial access to facilitate ambulation and subsequent safe removal without surgery or a closure device. Retrospective review of the experience with this approach at a single institution between September 2017 and February 2020 documented feasibility and safety. Baseline demographics, hemodynamic data, and clinical outcomes were collected. Thirty-eight patients had a total of 56 IABPs placed. There were no significant access site or cerebrovascular complications. One fifth of IABPs (21.4%) had balloon failure or migration, requiring placement of a new device, though no patients had significant complications from balloon failure. The majority (81.6%) of patients in the cohort on axillary IABP support were ambulatory and ultimately received the intended therapy (63.2% transplant, 13.2% durable left ventricular assist device, 5.3% other cardiac surgery). Percutaneous, axillary IABP is feasible and associated with an acceptable complication rate as a bridge to definitive therapy.
Abstract 3780: Cerebrospinal fluid-responsive factor SERPINA3 induces an increase in the malignancy of glioblastoma
Velazquez, Montserrat A. Lara, Carrano, Anna , Phillips, Jordan, Segovia, José , Chaichana, Kaisorn L. , Asmann, Yan W. , Hinojosa, Alfredo Quinones, Zarco, Natanael , Phillips, Jordan, Schiapparelli, Paula , Norton, Emily S. , Jeanneret, Stéphanie , Corona, Teresa , Guerrero‐Cazares, Hugo

Mayo Clinic

Cancer Research | September 4, 2020 | Volume: 80 | Issue: 16_Supplement | Pages: 3780-3780

10.1158/1538-7445.am2020-3780 Get It

Abstract Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adults with a median survival of 14 months despite multimodal treatment. Patients with GBM tumors exhibit a post-resection recurrence rate of almost 100%. The tumor recurrence and treatment resistance properties of GBM reside in a stem-like cell population called Brain Tumor Initiating Cells (BTIC). Among primary GBMs, periventricular tumors exhibit worse survival than tumors distal to the lateral ventricles (LV), the cause for this worse outcome is not known. A potential explanation is the proximity of these tumors to the cerebrospinal fluid (CSF) and the neurogenic niche in the sub-ventricular zone (SVZ). Chemotactic signals present in the cerebrospinal fluid (CSF) regulate neural progenitor cells migratory response and differentiation profile. Our preliminary data show that cancer-derived CSF induces an increase in the migration and proliferation of GBM cells when compared to non-cancer CSF. We evaluated the transcriptome of human GBM cells in response to cancer and non-cancer CSF and identified alpha-1-antichymotrypsin (SERPINA3) as one of the genes that show higher over expression upon cancer CSF-stimulation. SERPINA3 is a circulating anti-protease that is produced and released in different tissues such as liver, prostate, lungs, endometrium and brain that is over-expressed in multiple cancers. We hypothesize that the overexpression of SERPINA3 in response to CSF is a contributing factor to the increase malignancy of periventricular GBM tumors. We tested this hypothesis in silico, in vitro and in vivo. Using TCGA and Rembrandt databases we observed a higher expression of SERPINA3 in brain tumor tissue compared to controls with no differences among GBM subtypes. In GBM patients, expression of SERPINA3 negatively affects survival expectancy. In vitro, Using intraoperative samples, we confirmed that SERPINA3 is overexpressed in brain cancer tissue by western-blot and qRT-PCR. Interestingly, we observed a higher nuclear localization of SERPINA3 in cancer tissue and cells. To determine if SERPINA3 has an effect on the malignancy of GBM cells, we silenced its expression using shRNA. SERPINA3 silencing induced a decrease in cell proliferation (p&lt;0.05), as well as migration (p&lt;0.05), and invasion (p&lt;0.05). Remarkably CD133 expression and stem cell markers were decreased when SERPINA3 is silenced. In contrast, the addition of recombinant SERPINA3 induced an increase in cell migration (p&lt;0.05) of GBM cells. Moreover, cancer CSF is no longer able to induce an increase in GBM cell migration in SERPINA3-KD cells (p&lt;0.05). In vivo, mice orthotopically-injected with SERPINA3-KD cells showed a prolonged overall survival (p&lt;0.05). In summary, our results support the hypothesis that SERPINA3 plays a key role in GBM malignancy in response to CSF and its inhibition results in a better outcome using GBM preclinical models. Targeting the CSF-GBM interaction is a potential therapeutic approach that remains to be explored. Citation Format: Montserrat A. Lara Velazquez, Natanael Zarco, Anna Carrano, Jordan Phillips, Paula Schiapparelli, Emily S. Norton, Stephanie Jeanneret, Teresita Corona, Jose Segovia, Kaisorn Chaichana, Yan Asmann, Alfredo Quinones Hinojosa, Hugo Guerrero-Cazares. Cerebrospinal fluid-responsive factor SERPINA3 induces an increase in the malignancy of glioblastoma [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 3780.